CJC-1295 NO DAC 10mg - 49 € | Lab Peptides France

Name: CJC-1295 NO DAC
Brand: Lab Peptides France
SKU: cjc-1295-no-dac-10mg
Price: 49.00 EUR
Availability: InStock

Zoom

49,00 €

Impuestos incluidos • Entrega gratis desde 99€

+2,45 € en cashback de fidelidad, con una cuenta. Crear mi cuenta

19 en stock, listo para enviar

Prochain départ : samedi 3 octobre

Stock en Francia

Suscripción

44,10 €-10 %en lugar de 49,00 €

-10 % de por vida en cada cicloPause, salte o cancele en 1 clicSin compromiso, sin gastos ocultos

Tu kit completo

Vial 10mgIncluido
Agua bacteriostáticaAñadir
Jeringas de 1 mlAñadir

El vial por sí solo no puede usarse tal cual. Un vial sellado de CJC-1295 NO DAC 10mg, liofilizado, sin etiquetado individual.

No olvide lo imprescindible

Eau Bactériostatique

7,90 €

Seringue de précision 1ml 29Gx107,90 €

Lingettes alcool isopropylique 70%x103,90 €

Cartouches 3 mlx59,90 €

Aiguilles Stylo Injecteurx1010,90 €

Se compran juntos a menudo

Ipamorelin 5mg27,00 €

KPV 10mg34,00 €

Cagrilintide 5mg35,00 €

GHK-Cu 100mg49,00 €

CJC-1295 without DAC, also known as Mod GRF (1-29), is a synthetic analogue of the first 29 amino acids of human GHRH — the fragment that carries the hormone's activity on its own.

Four substitutions set it apart from the natural sequence: D-Ala2, which protects it from DPP-4 degradation, plus Gln8, Ala15 and Leu27, which improve its stability. The result is a half-life of about thirty minutes, against a few minutes for native GHRH.

The whole difference with CJC-1295 with DAC lies in what is missing: the Drug Affinity Complex, which binds the molecule to albumin and stretches its half-life to several days. Without it, action stays brief — and that is precisely what protocols seeking to preserve the natural pulsatility of growth hormone secretion are after, rather than flattening it.

This vial delivers 10 mg of CJC-1295 without DAC at HPLC purity of at least 98%. For research use only.

Science

01
Mecanismo de acción

GHRH acts on the GHRH-R receptor of somatotroph cells in the anterior pituitary, a G-protein coupled receptor. Its activation raises intracellular cyclic AMP, activates protein kinase A and triggers both the release of stored growth hormone and the transcription of its gene.

The D-Ala2 modification is the decisive one: it blocks the cleavage site of dipeptidyl peptidase-4, the enzyme that inactivates native GHRH within minutes. The other three substitutions limit oxidation and aggregation in solution.

The point that explains the frequent pairing with a GHRP such as Ipamorelin: the two families act on distinct receptors — GHRH-R on one side, GHS-R1a on the other — and through different signalling pathways. The literature describes a response greater than the sum of each taken alone, which is the documented basis for this combination.

By keeping a short action, the DAC-free analogue also lets somatostatin, the axis's physiological brake, express itself, which preserves the pulsatile character of secretion.

Clinical data

02Estudios clínicos

GHRH has been characterised since the 1980s and its 1-29 fragment, the shortest to retain full activity, is the basis of several analogues. Sermorelin, unmodified GHRH 1-29, was marketed as a diagnostic agent for somatotroph function, which solidly documents the overall mechanism.

Work on CJC-1295 clearly distinguishes the two versions. The version with DAC was the subject of early-phase trials showing sustained IGF-1 elevation over several days. The version without DAC, this one, is by contrast overwhelmingly documented in research literature and preclinical work, not by dedicated clinical trials.

Pairing with a GHRP is the best-described point: the combined effect of a GHRH analogue and a secretagogue acting on GHS-R1a is reported as greater than each taken alone, which remains consistent with the duality of signalling pathways.

No authority has evaluated CJC-1295 without DAC for therapeutic use. It is a research product.

Todavía no hay referencias para este péptido: busque en PubMed la literatura científica asociada.

Los estudios enumerados se facilitan únicamente con fines documentales y de investigación. No constituyen una indicación terapéutica ni una recomendación de uso humano. Este producto es estrictamente de uso exclusivo en laboratorio (RUO).

Lab workflow

03
Protocolos de investigación

Reconstitution. The 10 mg vial is reconstituted with 3 ml of bacteriostatic water, giving a 3.33 mg/ml solution. On a U-100 insulin syringe, 7.5 units then equal 250 mcg and 3 units equal 100 mcg. An alternative volume of 2 ml gives 5 mg/ml, for those wishing to reduce injected volume.

The vial is then full up to the neck: this is normal, it holds 3 ml at most. The 3 ml bacteriostatic water vial is enough.

Procedure: room temperature, septum disinfected with 70% isopropyl alcohol, slow injection along the wall, then gentle rolling between the palms until fully dissolved. Never shake vigorously.

Reported orders of magnitude. Research literature typically mentions 100 mcg per administration, one to three times daily, often away from lipid-rich meals which blunt the response. At 100 mcg three times daily, i.e. 300 mcg per day, a 10 mg vial represents roughly 33 days. At 100 mcg once daily, roughly 100 days. These figures are reported, not recommended.

Documented pairing. CJC-1295 without DAC combined with Ipamorelin is the most described secretagogue protocol in research literature, the two molecules acting on different receptors.

Reconstitución para este formato (10 mg)Volúmenes estándar utilizados en laboratorio

Agua añadida	Concentración	Marca de lectura
1 ml	10 mg/ml	10 UI = 1 mg
3 ml	3,33 mg/ml	40 UI = 1,33 mg

El volumen de agua no cambia el producto, solo su concentración. Introduzca el agua despacio por la pared del vial, nunca directamente sobre el liofilizado, y luego gírelo suavemente sin agitar. Las marcas se dan sobre una jeringa de 1 ml graduada en 100 unidades.

Asepsia

Desinfecte las superficies y los tapones (alcohol al 70%).

Disolvente

Extraiga el volumen necesario de agua bacteriostática.

Introducción

Inyecte suavemente contra la pared del vial (evite el chorro directo sobre el polvo).

Solubilización

Haga rodar el vial suavemente. No lo agite con fuerza (riesgo de degradación).

Conservación de la soluciónUna vez reconstituido: 2-8°C (nevera).

AdvertenciaHerramienta teórica para manipulación química. No constituye un consejo médico.

Abro la calculadora de dilución

Lo que es normal al recibirloLas observaciones que inquietan a los clientes y no son defectos

La cantidad de polvo parece mínima. Un liofilizado ocupa unos pocos milímetros en el fondo del vial, a veces solo una película translúcida. El peso indicado está ahí.
El polvo está compacto, pegado a la pared o al tapón. El transporte desplaza la torta liofilizada. No cambia nada en la reconstitución.
El vial no lleva etiqueta individual. Es nuestro embalaje estándar, no un vial de menor calidad.
Tras la reconstitución aparecen depósitos o filamentos. Es habitual, sobre todo con moléculas pequeñas. Deje que se asiente y haga rodar el vial entre las palmas, nunca lo agite.
El paquete es neutro. Nada en el exterior indica el contenido ni el nombre de la marca.

Lo que no es normal: un vial agrietado, una cápsula sin engastar o un tapón que se mueve, polvo que se ha licuado o cambiado de color. En esos casos concretos, escríbanos con una foto y recuperamos el vial.

Handling

04Conservación y manipulación

Unreconstituted lyophilised vial: stable for several months between 2 and 8 °C, several years at -20 °C, protected from light. Ambient-temperature transport does not degrade it.

After reconstitution: refrigerated between 2 and 8 °C, protected from light. The 0.9% benzyl alcohol in bacteriostatic water allows repeated draws over several weeks. Never freeze a reconstituted solution.

At 3 ml for 10 mg, a vial is drawn from over a long period: this is precisely the case where asepsis quality at each draw matters most. A fresh needle every time, a disinfected septum every time.

01How much water to reconstitute the 10 mg vial?

3 ml of bacteriostatic water, giving 3.33 mg/ml. On a U-100 syringe, 100 mcg then reads as 3 units and 250 mcg as 7.5 units. The vial is then full up to the neck: this is normal, it holds 3 ml at most. The 3 ml water vial is enough.

02What is the difference with CJC-1295 with DAC?

The affinity complex, and nothing else. With DAC, the molecule binds albumin and its half-life reaches several days, producing continuous elevation. Without DAC, it acts over about thirty minutes, which preserves the natural pulsatility of secretion. Two different profiles, not an inferior version.

03Why is it so often paired with Ipamorelin?

Because both act on distinct receptors: GHRH-R for CJC-1295, GHS-R1a for Ipamorelin. Research literature describes a combined response greater than each taken alone, which is why this pair is the most documented secretagogue protocol.

04How long does a 10 mg vial last?

10 mg is 10,000 mcg. At the quantities reported in the literature, 100 mcg three times daily i.e. 300 mcg per day, a vial represents roughly 33 days. At 100 mcg once daily, roughly 100 days. Actual autonomy depends on the chosen scheme.

05Are Mod GRF (1-29) and CJC-1295 without DAC the same thing?

Yes. Both names designate the same peptide: GHRH 1-29 modified at four positions, without affinity complex. "Mod GRF (1-29)" is the descriptive name, "CJC-1295 without DAC" the most widespread commercial one. The confusion arises because the CJC-1295 name also designates the DAC version, which is a different molecule.

06Must the solution be perfectly clear?

A light, uniform haze may appear and is not a defect. What justifies discarding a vial is particles that stay in suspension, a deposit that will not redissolve despite cold rest, or a yellow colour.

Benchmark

Péptidos similares

Against CJC-1295 with DAC. Same base peptide, one difference: the affinity complex binding the molecule to albumin. With DAC, half-life extends to several days and elevation becomes continuous — at the cost of pulsatility. Without DAC, action lasts about thirty minutes and lets somatostatin play its braking role. This is not a degraded version, it is a profile choice.

Against Ipamorelin. These are different families, and that is why they are paired: GHRH acts on GHRH-R, Ipamorelin is a GHRP acting on GHS-R1a. Two receptors, two pathways, a combined response described as greater than the sum of both.

Against Tesamorelin. Tesamorelin is also a GHRH analogue, but it is the only one in the class with FDA approval, obtained in 2010 for a specific indication. It is stabilised differently and its documented profile is clinical where CJC-1295 without DAC remains preclinical.

Against IGF-1 LR3. Opposite levels of action: CJC-1295 acts upstream on the pituitary and respects feedback loops, IGF-1 LR3 acts downstream, directly on the IGF-1R receptor.

CJC-1295 NO DAC 10mg Crecimiento Muscular

Factores de crecimiento

01
Mecanismo de acción

02Estudios clínicos

03
Protocolos de investigación

Asepsia

Disolvente

Introducción

Solubilización

04Conservación y manipulación

Péptidos similares

Factores de crecimiento

Información del producto

Asepsia

Disolvente

Introducción

Solubilización

Reactivos complementarios